Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer
Recruiting · NCT05864794 · Interventional (participants receive a specific treatment) · Lead sponsor: University Medical Center Groningen
View the official record on ClinicalTrials.gov →Interventions studied
MRI
What this trial is about
Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease will undergo an MRI of the brain to screen for brain disease.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment.
- Fit for systemic treatment (PS 0-2) according to standard of care.
- No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist.
Exclusion criteria
- Prior/concomitant therapy for stage IV disease.
- Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment.
- Contraindications for MRI scan with contrast as per standard of care protocol of the institution.
Where it is running
3 locations listed.
- Maastricht UMC+ - Maastricht, Netherlands
- Ommelander Ziekenhuisgroep - Scheemda, Netherlands
- University Medical Center Groningen - Groningen, Provincie Groningen, Netherlands